Multiply Labs' leverage of NVIDIA’s tech stack marks a turning point for a biomanufacturing industry that has historically relied on manual, "artisanal" processes. By integrating NVIDIA’s digital ...

Multiply Labs collaborated with these life science industry leaders to demonstrate automated cell therapy manufacturing tasks, with an emphasis on cell expansion. The results of the proof-of-concept ...

Cell therapies are among the most promising, yet complex medicines being developed today. Multiply Labs' mission is to make these therapies more widely available by increasing manufacturing efficiency ...

Portal Biotechnologies and Multiply Labs announced a collaboration with the goal of leveraging automation to accelerate product timelines and reduce costs, helping innovative cell therapies reach more ...

Multiply Labs, a robotics firm, and Retro Biosciences, which is developing therapies to address age-related diseases, signed an agreement valued at up to $85 million to automate Retro’s approach to ...

Breakthrough partnership with Universal Robots transforms "artisanal" manufacturing, making personalized, life-saving cancer treatments affordable and widely available. Leveraging collaborative robots ...

Multiply Labs, a San Francisco-based robotics company developing advanced automated manufacturing systems for cell therapies, announced an expansion of its collaboration with Thermo Fisher Scientific.

Collaboration with AstraZeneca will focus on scaling cell therapy manufacturing using GMP-ready end-to-end robotic biomanufacturing technologySAN FRANCISCO--(BUSINESS WIRE)--#AstraZeneca--Multiply ...

Multiply Labs, a leader in robotic biomanufacturing, today announced a landmark milestone in its mission to scale production of cell and gene therapies; The company is now leveraging NVIDIA’s open ...

Multiply Labs, a leader in robotic biomanufacturing, today announced a landmark milestone in its mission to scale production of cell and gene therapies; The company is now leveraging NVIDIA's open ...